Glenzocimab for REperfusion in the Setting of Endovascular Therapy for Brain infarctioN: GREEN Study

Status: Recruiting

Phase of Trial: Phase II/III

Latest Information Update: 12 Jan 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

09 Jan 2023 According to an Acticor Biotech media release, 1 patient recruited till date and an interim analysis will be performed after the first 78 patients are included and is expected end of 2023.
09 Jan 2023 According to an Acticor Biotech media release, this trial is conducted under the auspices of the Paris Public Hospitals (Assistance Publique-Hopitaux de Paris), and is part of the RHU BOOSTER, receiving financial support from the French National Research Agency (Agence Nationale de la Recherche) and the Government's 'Investments for the Future' program (Programme Investissements d'Avenir).
09 Jan 2023 Status changed from not yet recruiting to recruiting, according to an Acticor Biotech media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com